RYTM Q2 2018 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$15M

Net Income

-$14M

EPS (Diluted)

$-0.52

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$292M

Total Liabilities

$7M

Stockholders' Equity

$284M

Cash & Equivalents

$210M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$15M	-$7M	-122.4%
Net Income	-$14M	-$7M	-111.9%